This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
drug delivery | 1014 |
drug discovery | 576 |
clinical trials | 571 |
side effects | 445 |
drug repurposing | 430 |
health care | 396 |
mg kg | 385 |
breast cancer | 362 |
cancer cells | 352 |
acute respiratory | 336 |
respiratory syndrome | 332 |
case report | 325 |
kcal mol | 305 |
amino acid | 292 |
novel coronavirus | 292 |
virtual screening | 286 |
infectious diseases | 284 |
outcome measures | 283 |
main outcome | 281 |
antiviral activity | 277 |
adverse effects | 266 |
public health | 259 |
clinical trial | 256 |
please specify | 254 |
abstract type | 254 |
severe acute | 249 |
main protease | 249 |
drug administration | 248 |
drug development | 244 |
lung cancer | 239 |
drug repositioning | 234 |
drug design | 233 |
delivery systems | 231 |
coronavirus disease | 214 |
drug interactions | 214 |
may also | 210 |
immune response | 209 |
drug release | 205 |
drug resistance | 204 |
approved drugs | 204 |
growth factor | 203 |
syndrome coronavirus | 199 |
intravenous drip | 198 |
cord uid | 196 |
antiviral drugs | 196 |
gene expression | 196 |
doc id | 196 |
epithelial cells | 195 |
cell lines | 191 |
virus infection | 184 |
united states | 181 |
delivery system | 180 |
methods materials | 168 |
molecular docking | 168 |
viral infections | 166 |
based drug | 166 |
combination therapy | 161 |
viral replication | 160 |
respiratory tract | 159 |
widely used | 159 |
molecular weight | 156 |
drug therapy | 152 |
research abstract | 151 |
abstract background | 150 |
drug targets | 149 |
natural products | 149 |
activated charcoal | 147 |
systematic review | 139 |
rheumatoid arthritis | 138 |
antiviral drug | 135 |
adverse drug | 135 |
clinical studies | 134 |
active site | 134 |
lymph nodes | 134 |
risk factors | 131 |
antimicrobial drugs | 129 |
adverse events | 129 |
drug candidates | 128 |
carbon nanotubes | 127 |
adsorption energy | 127 |
protease inhibitors | 127 |
cancer therapy | 126 |
therapeutic agents | 124 |
molecular dynamics | 123 |
blood pressure | 123 |
world health | 122 |
anticancer drug | 122 |
important role | 122 |
drug reactions | 121 |
animal models | 121 |
lopinavir ritonavir | 121 |
binding site | 120 |
amino acids | 120 |
cell culture | 119 |
stem cells | 119 |
antiviral agents | 118 |
small molecules | 118 |
drug use | 117 |
virus replication | 117 |
lung disease | 116 |
commonly used | 116 |
new drug | 115 |
immune system | 114 |
cell death | 114 |
magnetic resonance | 114 |
rna polymerase | 114 |
intensive care | 113 |
health organization | 113 |
severe covid | 112 |
clinical practice | 112 |
acquired pneumonia | 112 |
small intestine | 110 |
patients treated | 110 |
endothelial cells | 110 |
clinical pharmacy | 109 |
epidermal necrolysis | 108 |
toxic epidermal | 107 |
small molecule | 107 |
crystal structure | 106 |
immunodeficiency virus | 106 |
binding affinity | 105 |
converting enzyme | 105 |
anticancer drugs | 104 |
ebola virus | 104 |
targeted delivery | 104 |
laboratory animals | 104 |
descriptive abstract | 103 |
antimicrobial drug | 103 |
influenza virus | 103 |
potential drug | 102 |
least one | 102 |
nervous system | 102 |
gene delivery | 100 |
gastrointestinal tract | 100 |
tumor cells | 100 |
infected patients | 100 |
drug binding | 99 |
free energy | 99 |
wide range | 98 |
may occur | 98 |
lung injury | 98 |
cell line | 98 |
middle east | 98 |
imaging findings | 98 |
viral infection | 98 |
human immunodeficiency | 97 |
medication reconciliation | 97 |
east respiratory | 97 |
drug combinations | 97 |
pharmaceutical care | 97 |
phase i | 96 |
cystic fibrosis | 96 |
clinical pharmacist | 95 |
mg ml | 95 |
matrix completion | 94 |
new drugs | 94 |
nmr spectroscopy | 93 |
fda approved | 92 |
heart failure | 92 |
acid composition | 92 |
respiratory distress | 92 |
hydrogen bonds | 92 |
protein binding | 92 |
infectious disease | 92 |
pulmonary fibrosis | 91 |
phase ii | 91 |
host cell | 91 |
protein kinase | 91 |
cell proliferation | 91 |
drug molecules | 90 |
cancer cell | 90 |
renal failure | 90 |
spike protein | 90 |
gene therapy | 90 |
binding sites | 89 |
mean age | 89 |
binding energy | 88 |
energy gap | 88 |
surface area | 88 |
drug treatment | 88 |
critically ill | 87 |
protease inhibitor | 87 |
dry powder | 87 |
oxidative stress | 87 |
resistant bacteria | 87 |
oral administration | 86 |
causative microorganisms | 86 |
mouse model | 86 |
hepatocellular carcinoma | 86 |
monoclonal antibodies | 85 |
present study | 85 |
years old | 84 |
control group | 84 |
acid glycoprotein | 84 |
leading edge | 84 |
existing drugs | 84 |
bone marrow | 83 |
pediatric patients | 82 |
hydrogen bond | 82 |
central nervous | 82 |
machine learning | 82 |
sars coronavirus | 81 |
cancer patients | 80 |
mental health | 80 |
serum albumin | 80 |
broad spectrum | 80 |
new york | 80 |
patients receiving | 79 |
particle size | 79 |
epidermal growth | 79 |
sjs ten | 79 |
pulmonary disease | 78 |
increased risk | 78 |
cancer treatment | 78 |
immune responses | 78 |
therapeutic efficacy | 78 |
spectrum antiviral | 78 |
responsive systems | 77 |
hiv aids | 77 |
synthetic biology | 77 |
electron microscopy | 77 |
retrospective study | 77 |
controlled trial | 76 |
nucleic acids | 76 |
mass spectrometry | 76 |
ion channel | 75 |
like protease | 74 |
mg twice | 74 |
may lead | 74 |
university hospital | 74 |
host cells | 74 |
adverse reactions | 74 |
mg day | 73 |
lipid nanoparticles | 73 |
associated pneumonia | 73 |
plasma concentrations | 73 |
outsourcing facilities | 73 |
high doses | 73 |
nucleic acid | 73 |
cancer stem | 73 |
distress syndrome | 72 |
biomedical applications | 72 |
pharmaceutical industry | 72 |
recent years | 72 |
infected cells | 71 |
targeted drug | 71 |
dependent rna | 70 |
drug target | 70 |
body weight | 70 |
johnson syndrome | 70 |
ill patients | 70 |
drug interaction | 69 |
author funder | 69 |
pseudo amino | 69 |
large number | 69 |
herpes simplex | 69 |
prostate cancer | 69 |
granted medrxiv | 69 |
hospitalized patients | 68 |
medication adherence | 68 |
commercially available | 68 |
lupus erythematosus | 68 |
zika virus | 68 |
personalized medicine | 68 |
blood vessels | 68 |
may result | 68 |
ng ml | 68 |
cell types | 68 |
even though | 68 |
another study | 67 |
solid lipid | 67 |
sodium bicarbonate | 67 |
per patient | 67 |
cohort study | 67 |
two different | 67 |
aspiration pneumonia | 67 |
recent advances | 67 |
may cause | 67 |
clinical use | 67 |
human lung | 66 |
care unit | 66 |
health services | 66 |
viral rna | 66 |
deep learning | 66 |
hiv infection | 66 |
throughput screening | 66 |
blood flow | 66 |
primary care | 65 |
emergency department | 65 |
nitric oxide | 65 |
dna damage | 65 |
protein interaction | 65 |
antimicrobial activity | 65 |
controlled release | 65 |
dendritic cells | 64 |
viral load | 64 |
lymph node | 64 |
effective treatment | 64 |
high risk | 64 |
target cells | 64 |
brain barrier | 64 |
approved drug | 64 |
observational study | 64 |
type ii | 64 |
treatment options | 64 |
therapeutic options | 64 |
renal function | 63 |
factor receptor | 63 |
recent study | 63 |
type i | 63 |
necrosis factor | 63 |
respiratory diseases | 62 |
related problems | 62 |
computational methods | 62 |
community pharmacies | 62 |
copyright holder | 62 |
protein expression | 62 |
cell surface | 62 |
medical devices | 62 |
peer review | 62 |
ion channels | 62 |
chronic hepatitis | 62 |
molecular mechanisms | 62 |
peritoneal dialysis | 61 |
type diabetes | 61 |
salivary glands | 61 |
drug courts | 61 |
pediatric radiology | 61 |
treat covid | 61 |
lung diseases | 61 |
healthy volunteers | 61 |
case reports | 61 |
drugs may | 61 |
will also | 61 |
also known | 61 |
protein interactions | 61 |
hybrid nanoparticles | 61 |
randomized clinical | 60 |
cell membrane | 60 |
performed using | 60 |
elderly patients | 60 |
monoclonal antibody | 60 |
binding free | 60 |
mechanical ventilation | 60 |
study group | 59 |
computed tomography | 59 |
liver disease | 59 |
many cases | 59 |
ncov sars | 59 |
literature review | 59 |
receptor antagonist | 59 |
inflammatory drugs | 59 |
total number | 59 |
md simulation | 59 |
recent studies | 58 |
also reported | 58 |
also used | 58 |
drug screening | 58 |
drug metabolism | 58 |
heart disease | 58 |
like particles | 58 |
repurposable drugs | 58 |
drugs used | 58 |
potential drugs | 58 |
different types | 58 |
clinical pharmacists | 58 |
differential diagnosis | 58 |
statistically significant | 58 |
pilot study | 58 |
harm reduction | 57 |
clinical outcomes | 57 |
drug users | 57 |
pregnant women | 57 |
mortality rate | 57 |
drug sales | 57 |
phase iii | 57 |
coronavirus infection | 57 |
staphylococcus aureus | 57 |
study showed | 57 |
antiviral therapy | 57 |
lung tissue | 57 |
excess proton | 57 |
oral delivery | 57 |
animal model | 56 |
pseudomonas aeruginosa | 56 |
controlled drug | 56 |
escherichia coli | 56 |
fold higher | 56 |
chemical structure | 56 |
respiratory disease | 56 |
cell lung | 56 |
pulmonary drug | 56 |
stem cell | 56 |
ethylene glycol | 56 |
tumor growth | 56 |
binding pocket | 56 |
polymeric nanoparticles | 56 |
severe cases | 56 |
new coronavirus | 55 |
candidate drugs | 55 |
drug reaction | 55 |
plasma proteins | 55 |
boron nitride | 55 |
dengue virus | 55 |
one patient | 55 |
liver injury | 55 |
also found | 55 |
alveolar macrophages | 54 |
disease progression | 54 |
free drug | 54 |
cov infection | 54 |
intravenous injection | 54 |
computational approaches | 54 |
high throughput | 54 |
community pharmacy | 54 |
significant differences | 54 |
prospective study | 54 |
simplex virus | 54 |
patient care | 54 |
knowledge graph | 54 |
mycobacterium tuberculosis | 54 |
randomized controlled | 54 |
patient safety | 54 |
cellular uptake | 54 |
colorectal cancer | 53 |
drug products | 53 |
gold nanoparticles | 53 |
health professionals | 53 |
dress dihs | 53 |
rights reserved | 53 |
resonance imaging | 53 |
data sets | 53 |
plasma membrane | 53 |
kg times | 52 |
high dose | 52 |
long term | 52 |
significantly higher | 52 |
antibacterial activity | 52 |
cancer drugs | 52 |
several studies | 52 |
substance use | 52 |
potential therapeutic | 52 |
antiretroviral therapy | 52 |
reactive oxygen | 52 |
potential inhibitors | 52 |
solid tumors | 52 |
drug absorption | 52 |
two groups | 52 |
host proteins | 52 |
target interaction | 51 |
previous studies | 51 |
gastric cancer | 51 |
pulmonary hypertension | 51 |
uv light | 51 |
virus type | 51 |
therapeutic targets | 51 |
two drugs | 51 |
significant difference | 51 |
ligand binding | 51 |
medical device | 51 |
innate immune | 51 |
high affinity | 51 |
hiv protease | 51 |
clinical pharmacology | 51 |
cell cultures | 51 |
structural proteins | 50 |
folic acid | 50 |
active compounds | 50 |
data analysis | 50 |
human coronavirus | 50 |
chronic obstructive | 50 |
vivo studies | 50 |
viral diseases | 50 |
heart rate | 50 |
antimicrobial agents | 50 |
adverse effect | 50 |
oral bioavailability | 50 |
enzyme activity | 50 |
md simulations | 50 |
spinal cord | 49 |
high levels | 49 |
kidney disease | 49 |
drug concentration | 49 |
reverse transcriptase | 49 |
crucial role | 49 |
well known | 49 |
traditional chinese | 49 |
tumor necrosis | 49 |
compassionate use | 49 |
per day | 49 |
metabolic acidosis | 49 |
soft tissue | 49 |
plasma protein | 49 |
peripheral blood | 49 |
signaling pathways | 49 |
many drugs | 49 |
calcium channel | 49 |
cancer drug | 49 |
lactic acid | 48 |
tyrosine kinase | 48 |
ray crystallography | 48 |
drug shortages | 48 |
systemic lupus | 48 |
new therapeutic | 48 |
patients received | 48 |
viral proteins | 48 |
cell cycle | 48 |
inflammatory response | 48 |
clinical characteristics | 48 |
inhibitory activity | 48 |
kinase inhibitor | 48 |
results suggest | 48 |
chloroquine phosphate | 47 |
statistical analysis | 47 |
among patients | 47 |
human protein | 47 |
clinical features | 47 |
drug concentrations | 47 |
human body | 47 |
single dose | 47 |
myocardial infarction | 47 |
human serum | 47 |
also observed | 47 |
safety profile | 47 |
human plasma | 47 |
rats treated | 47 |
wide variety | 47 |
vitro studies | 47 |
lymphatic system | 47 |
qt prolongation | 46 |
will discuss | 46 |
medical center | 46 |
gastric mucosa | 46 |
iron oxide | 46 |
molecular targets | 46 |
adverse event | 46 |
atrial fibrillation | 46 |
sustained release | 46 |
diabetes mellitus | 46 |
drug hypersensitivity | 46 |
inflammatory bowel | 46 |
human health | 46 |
significantly increased | 46 |
also shown | 46 |
kg day | 46 |
antiviral agent | 46 |
pulmonary delivery | 46 |
cl pro | 45 |
last years | 45 |
care units | 45 |
smooth muscle | 45 |
endoplasmic reticulum | 45 |
toxic effects | 45 |
results showed | 45 |
cell viability | 45 |
pdb id | 45 |
medical records | 45 |
clinical symptoms | 45 |
alkaline phosphatase | 45 |
therapeutic drug | 45 |
respiratory syncytial | 45 |
data set | 45 |
per year | 45 |
chloroquine hydroxychloroquine | 45 |
specific drug | 45 |
human cell | 45 |
higher risk | 45 |
significantly reduced | 45 |
valproic acid | 44 |
target interactions | 44 |
immune cells | 44 |
transplant recipients | 44 |
inhibitory effect | 44 |
neural networks | 44 |
syncytial virus | 44 |
high concentrations | 44 |
drug susceptibility | 44 |
inflammatory cytokines | 44 |
based approach | 44 |
risk factor | 44 |
oxygen species | 44 |
plasmodium falciparum | 44 |
van der | 44 |
community pharmacists | 43 |
three different | 43 |
results obtained | 43 |
relatively low | 43 |
blood glucose | 43 |
clinically relevant | 43 |
health promotion | 43 |
high level | 43 |
effi cacy | 43 |
cytokine storm | 43 |
among others | 43 |
ml min | 43 |
radiation dose | 43 |
authors declare | 43 |
first time | 43 |
physicochemical properties | 43 |
neural network | 43 |
obstructive pulmonary | 43 |
ovarian cancer | 43 |
findings suggest | 43 |
well tolerated | 43 |
antiviral effects | 43 |
therapeutic effect | 43 |
hydrogen bonding | 42 |
cardiovascular disease | 42 |
charge transfer | 42 |
drug combination | 42 |
steroidal anti | 42 |
angiotensin ii | 42 |
force field | 42 |
many years | 42 |
respiratory infectious | 42 |
clinical data | 42 |
antibiotic resistance | 42 |
chronic diseases | 42 |
fusion protein | 42 |
drug loading | 42 |
bowel disease | 42 |
metastatic breast | 42 |
kinase inhibitors | 42 |
ex vivo | 42 |
target proteins | 42 |
binding protein | 42 |
edge pseudopod | 42 |
wound healing | 42 |
data collection | 42 |
medicinal chemistry | 42 |
drug related | 41 |
plasma concentration | 41 |
study reported | 41 |
intravenous administration | 41 |
silver nanoparticles | 41 |
vitro antiviral | 41 |
toxicity studies | 41 |
antimalarial drugs | 41 |
room temperature | 41 |
clinical efficacy | 41 |
silico drug | 41 |
upper respiratory | 41 |
critical role | 41 |
repurposed drugs | 41 |
image quality | 41 |
interstitial lung | 41 |
million people | 41 |
life cycle | 41 |
significantly lower | 41 |
antiviral activities | 41 |
will provide | 41 |
renal impairment | 41 |
patients infected | 41 |
acute lung | 41 |
drug carrier | 41 |
pulmonary tuberculosis | 41 |
lymphoid tissue | 40 |
drug effects | 40 |
medrxiv preprint | 40 |
interstitial pneumonia | 40 |
anticancer activity | 40 |
mg dl | 40 |
viral entry | 40 |
autoimmune diseases | 40 |
low ph | 40 |
naturally occurring | 40 |
human disease | 40 |
tract infections | 40 |
lamina propria | 40 |
past years | 40 |
may provide | 40 |
first step | 40 |
one study | 40 |
human cells | 40 |
new insights | 40 |
last decade | 40 |
drug carriers | 40 |
der waals | 40 |
dose activated | 40 |
pediatric population | 40 |
fatty acid | 40 |
pharmacy services | 40 |
tumor cell | 39 |
plant extracts | 39 |
epithelial cell | 39 |
pharmaceutical interventions | 39 |
key role | 39 |
allowed without | 39 |
adult patients | 39 |
sbt abpc | 39 |
mr imaging | 39 |
drug safety | 39 |
flow cytometry | 39 |
white matter | 39 |
mechanical properties | 39 |
without permission | 39 |
estrogen receptor | 39 |
small cell | 39 |
better understanding | 39 |
matrix factorization | 39 |
pharmaceutical companies | 39 |
mast cells | 39 |
dynamics simulation | 39 |
reuse allowed | 39 |
alveolar damage | 39 |
care providers | 39 |
results indicate | 39 |
natural product | 39 |
polymeric nanocarriers | 39 |
critical care | 38 |
taken together | 38 |
oral drug | 38 |
dose adjustment | 38 |
intestinal metaplasia | 38 |
gene transfer | 38 |
disease control | 38 |
gi tract | 38 |
currently available | 38 |
low dose | 38 |
goblet cells | 38 |
urinary tract | 38 |
corona virus | 38 |
blood cells | 38 |
signal transduction | 38 |
low molecular | 38 |
patients may | 38 |
patients undergoing | 38 |
transgenic mice | 38 |
biological activity | 38 |
protein structures | 38 |
results show | 38 |
diffuse alveolar | 38 |
poster sessions | 38 |
target protein | 38 |
significant increase | 37 |
controlled trials | 37 |
based virtual | 37 |
oral anticoagulants | 37 |
animal studies | 37 |
therapeutic potential | 37 |
hiv drugs | 37 |
contrast agents | 37 |
york city | 37 |
drug may | 37 |
magnetic nanoparticles | 37 |
drug supply | 37 |
urgent need | 37 |
antimicrobial peptides | 37 |
may help | 37 |
inflammatory diseases | 37 |
pancreatic cancer | 37 |
fold increase | 37 |
small intestinal | 37 |
sales data | 37 |
angiotensin converting | 37 |
negative bacteria | 37 |
oxide nanoparticles | 37 |
receptor blockers | 37 |
general population | 37 |
respiratory system | 37 |
may require | 37 |
binding domain | 37 |
therapeutic drugs | 37 |
pleural effusion | 37 |
therapeutic strategies | 36 |
potential targets | 36 |
clinical development | 36 |
tract infection | 36 |
platelet aggregation | 36 |
network pharmacology | 36 |
treated patients | 36 |
often used | 36 |
puerto rico | 36 |
nuclear magnetic | 36 |
drug overdose | 36 |
medicinal plants | 36 |
two types | 36 |
cardiovascular diseases | 36 |
inhibitory effects | 36 |
median age | 36 |
functional groups | 36 |
identify potential | 36 |
helicobacter pylori | 36 |
rna viruses | 36 |
interstitial fibrosis | 36 |
hypersensitivity reactions | 36 |
acetylsalicylic acid | 36 |
inclusion criteria | 36 |
therapeutic target | 35 |
coupled receptor | 35 |
silico pharmacology | 35 |
data suggest | 35 |
drug monitoring | 35 |
human primates | 35 |
risk assessment | 35 |
computational drug | 35 |
structural basis | 35 |
congenital heart | 35 |
emergency use | 35 |
virus entry | 35 |
disulfide bond | 35 |
twice daily | 35 |
side effect | 35 |
liver failure | 35 |
protein synthesis | 35 |
effective drug | 35 |
high resolution | 35 |
drug efficacy | 35 |
drug resistant | 35 |
inflammatory cells | 35 |
early stages | 35 |
plasma levels | 35 |
rna virus | 35 |
tumor microenvironment | 35 |
drug response | 35 |
salivary gland | 35 |
nuclear receptors | 35 |
chemotherapeutic agents | 35 |
target site | 35 |
wild type | 35 |
weight loss | 35 |
novel drug | 35 |
responsive system | 35 |
dependent manner | 35 |
two main | 35 |
potential treatment | 34 |
clinical management | 34 |
acid residues | 34 |
discovery process | 34 |
antitumor activity | 34 |
systemic circulation | 34 |
liver function | 34 |
genetic variants | 34 |
global health | 34 |
rna synthesis | 34 |
negatively charged | 34 |
dose reduction | 34 |
imaging features | 34 |
based screening | 34 |
natural compounds | 34 |
chemical shift | 34 |
transcription factor | 34 |
respiratory failure | 34 |
clinical applications | 34 |
signaling pathway | 34 |
made available | 34 |
clinically approved | 34 |
single cell | 34 |
walled carbon | 34 |
red blood | 34 |
developing countries | 34 |
hospital pharmacy | 34 |
three times | 34 |
use drugs | 34 |
induced lung | 34 |
previously described | 34 |
inject drugs | 34 |
care system | 34 |
nursing home | 34 |
supportive care | 34 |
traditional medicine | 34 |
clinically significant | 33 |
molecular mechanism | 33 |
human interactome | 33 |
retrospective review | 33 |
cell type | 33 |
selected drugs | 33 |
adrenergic receptor | 33 |
chinese medicine | 33 |
underlying disease | 33 |
triple helix | 33 |
polyethylene glycol | 33 |
infl uence | 33 |
supply chain | 33 |
healthcare professionals | 33 |
chemical structures | 33 |
like proteinase | 33 |
may increase | 33 |
pharmacy department | 33 |
human proteins | 33 |
ace inhibitors | 33 |
clinical presentation | 33 |
crystal structures | 33 |
drugs targeting | 33 |
antiviral effect | 33 |
two decades | 33 |
graph regularized | 33 |
drug sharing | 33 |
potential antiviral | 33 |
convalescent plasma | 33 |
cell entry | 33 |
health status | 33 |
treating covid | 32 |
drug allergy | 32 |
hydrophobic interactions | 32 |
membrane protein | 32 |
artificial intelligence | 32 |
biologically active | 32 |
small bowel | 32 |
potent inhibitor | 32 |
protein data | 32 |
american college | 32 |
molecule inhibitors | 32 |
respiratory infections | 32 |
mrna expression | 32 |
drug candidate | 32 |
innate immunity | 32 |
health insurance | 32 |
coupled receptors | 32 |
gastric lavage | 32 |
synergistic effect | 32 |
mouse models | 32 |
disulfide bonds | 32 |
successful treatment | 32 |
internal medicine | 32 |
transplant patients | 32 |
also showed | 32 |
ms ms | 32 |
cutaneous adverse | 32 |
many patients | 32 |
clinical research | 32 |
pharmacophore model | 32 |
receptor binding | 32 |
vascular endothelial | 32 |
significant reduction | 32 |
mesoporous silica | 31 |
patients taking | 31 |
loading dose | 31 |
see table | 31 |
current status | 31 |
viral genome | 31 |
membrane proteins | 31 |
nir light | 31 |
systemic symptoms | 31 |
drug court | 31 |
encapsulation efficiency | 31 |
aag levels | 31 |
healthy subjects | 31 |
multidisciplinary team | 31 |
angiotensin receptor | 31 |
multidrug resistance | 31 |
intestinal mucosa | 31 |
posterior fossa | 31 |
molecular structure | 31 |
pulmonary toxicity | 31 |
orally administered | 31 |
light light | 31 |
chronic inflammatory | 31 |
chronic kidney | 31 |
therapeutic effects | 31 |
electrostatic interactions | 31 |
mortality rates | 31 |
data bank | 31 |
antiretroviral drugs | 31 |
protein structure | 31 |
clinical impact | 31 |
clinical course | 31 |
induced pulmonary | 31 |
care professionals | 31 |
gastric acid | 31 |
study period | 31 |
early stage | 31 |
fetal mri | 31 |
intended use | 30 |
year period | 30 |
bacterial infection | 30 |
medication review | 30 |
preclinical studies | 30 |
cell hyperplasia | 30 |
multiple myeloma | 30 |
publicly available | 30 |
severe cutaneous | 30 |
human genome | 30 |
pharmacist intervention | 30 |
frequently used | 30 |
mediterranean fever | 30 |
investigational drugs | 30 |
patients using | 30 |
enzyme inhibitors | 30 |
may become | 30 |
data mining | 30 |
magnetic field | 30 |
recently published | 30 |
antibiotic therapy | 30 |
recently emerged | 30 |
retrospective cohort | 30 |
qt interval | 30 |
several drugs | 30 |
fatty acids | 30 |
delivery applications | 30 |
also cause | 30 |
metabolizing enzymes | 30 |
contrast agent | 30 |
cytokine release | 30 |
may produce | 30 |
young children | 30 |
septic shock | 30 |
familial mediterranean | 30 |
network proximity | 30 |
studies using | 30 |
virus infections | 30 |
lower respiratory | 30 |
clinical study | 30 |
health problems | 30 |
drug exposure | 30 |
growth hormone | 30 |
bovine serum | 30 |
growth factors | 30 |
times higher | 30 |
mononuclear cells | 30 |
active metabolite | 30 |
acid secretion | 30 |
also provide | 30 |
experimental data | 30 |
docking study | 29 |
diseased tissues | 29 |
treatment strategies | 29 |
aerosol therapy | 29 |
fda approval | 29 |
fi rst | 29 |
factors associated | 29 |
electron microscopic | 29 |
future studies | 29 |
viral protein | 29 |
patients admitted | 29 |
patients without | 29 |
connective tissue | 29 |
binding affinities | 29 |
left ventricular | 29 |
cell growth | 29 |
sequence identity | 29 |
recently reported | 29 |
chemotherapeutic drugs | 29 |
coronary artery | 29 |
tissue engineering | 29 |
ongoing clinical | 29 |
real time | 29 |
imaging modalities | 29 |
total drug | 29 |
oral cavity | 29 |
urban health | 29 |
imaging studies | 29 |
enrichment analysis | 29 |
two patients | 29 |
colon cancer | 29 |
lactic acidosis | 29 |
effectively inhibit | 29 |
inflammatory responses | 29 |
blood samples | 29 |
next generation | 29 |
expression levels | 29 |
quality control | 29 |
therapeutic intervention | 29 |
size distribution | 29 |
better understand | 29 |
pharmacokinetic parameters | 29 |
liver transplant | 29 |
western blot | 29 |
serine protease | 29 |
std nmr | 29 |
dft theory | 29 |
active targeting | 29 |
liposomal doxorubicin | 29 |
rna replication | 29 |
cell populations | 29 |
average age | 28 |
biological activities | 28 |
disease caused | 28 |
idiopathic pulmonary | 28 |
systems biology | 28 |
genetic polymorphisms | 28 |
currently used | 28 |
injection drug | 28 |
developing new | 28 |
bacterial infections | 28 |
multiple sclerosis | 28 |
physical examination | 28 |
biological systems | 28 |
activity relationship | 28 |
silica nanoparticles | 28 |
clinical benefit | 28 |
computational approach | 28 |
nasal cavity | 28 |
three main | 28 |
using different | 28 |
quantum dots | 28 |
flexible endoscopes | 28 |
potential use | 28 |
neurodegenerative diseases | 28 |
rational design | 28 |
pulmonary oedema | 28 |
predictive value | 28 |
marine natural | 28 |
essential role | 28 |
like cells | 28 |
carbon nanotube | 28 |
years ago | 28 |
transcription factors | 28 |
dipole moment | 28 |
antisense oligonucleotides | 28 |
molecular modeling | 28 |
urban areas | 28 |
drug eruptions | 28 |
training set | 28 |
viral vectors | 28 |
cell membranes | 28 |
substance abuse | 28 |
biological processes | 28 |
label use | 27 |
nonsteroidal anti | 27 |
cns disorders | 27 |
cell migration | 27 |
previously reported | 27 |
logistic regression | 27 |
may induce | 27 |
will focus | 27 |
injection site | 27 |
endothelial growth | 27 |
drug companies | 27 |
two major | 27 |
therapeutic response | 27 |
epr effect | 27 |
interactome network | 27 |
virus disease | 27 |
test drug | 27 |
target cell | 27 |
gram staining | 27 |
drug targeting | 27 |
higher concentrations | 27 |
adsorption energies | 27 |
possible drug | 27 |
rapid development | 27 |
replication cycle | 27 |
receptor activation | 27 |
health system | 27 |
early diagnosis | 27 |
teaching hospital | 27 |
viral dna | 27 |
interaction prediction | 27 |
various types | 27 |
individual patients | 27 |
san francisco | 27 |
study shows | 27 |
human diseases | 27 |
first line | 27 |
relatively high | 27 |
educational content | 27 |
ellagic acid | 27 |
one drug | 27 |
pl pro | 27 |
limited number | 27 |
health centre | 27 |
molecular basis | 27 |
studies showed | 27 |
less likely | 27 |
resistance mutations | 27 |
pediatric radiologists | 27 |
national institute | 27 |
may contribute | 27 |
effective drugs | 27 |
near future | 27 |
coronavirus infections | 27 |
experimental study | 27 |
clinical relevance | 27 |
test set | 27 |
among people | 27 |
new approach | 27 |
patients hospitalized | 27 |
dna synthesis | 27 |
current study | 27 |
protein sequence | 27 |
two weeks | 27 |
passive targeting | 27 |
exanthematous pustulosis | 26 |
avian influenza | 26 |
clinical outcome | 26 |
body temperature | 26 |
living cells | 26 |
structural information | 26 |
line treatment | 26 |
research groups | 26 |
endothelial cell | 26 |
inner city | 26 |
antimalarial drug | 26 |
income countries | 26 |
drug used | 26 |
drug abuse | 26 |
rat model | 26 |
health service | 26 |
action potential | 26 |
dna polymerase | 26 |
silico screening | 26 |
drugs using | 26 |
primary health | 26 |
significantly associated | 26 |
will help | 26 |
normal cells | 26 |
recent developments | 26 |
several years | 26 |
presentation will | 26 |
negative individuals | 26 |
cancer chemotherapy | 26 |
skeletal muscle | 26 |
rapid identification | 26 |
administration period | 26 |
vaccine delivery | 26 |
acute phase | 26 |
initial treatment | 26 |
national health | 26 |
scanning electron | 26 |
proton pump | 26 |
physical properties | 26 |
opioid use | 26 |
also occur | 26 |
network analysis | 26 |
nmr spectra | 26 |
graphene oxide | 26 |
antiviral research | 26 |
water molecules | 26 |
street youth | 26 |
mammalian cells | 26 |
many different | 26 |
chronic bronchitis | 26 |
state nmr | 26 |
drug addition | 26 |
dna repair | 26 |
states food | 26 |
data collected | 26 |
see section | 26 |
medication errors | 26 |
brain mri | 26 |
emerged novel | 26 |
aerosol delivery | 26 |
large scale | 26 |
study conducted | 26 |
major role | 26 |
comparative study | 26 |
use disorder | 26 |
primary human | 26 |
less toxic | 26 |
lung deposition | 26 |
ammonium group | 26 |
chloroquine effectively | 26 |
vast majority | 26 |
high quality | 26 |
aqueous solution | 26 |
rna interference | 26 |
therapeutic index | 26 |
pharmacy service | 26 |
human skin | 25 |
disease prevention | 25 |
inflammatory agents | 25 |
multiple drugs | 25 |
may act | 25 |
economic impact | 25 |
knockout mice | 25 |
severe pneumonia | 25 |
protein subcellular | 25 |
interferon beta | 25 |
clinical effects | 25 |
transforming growth | 25 |
dft study | 25 |
already approved | 25 |
social media | 25 |
significantly different | 25 |
alveolar epithelial | 25 |
higher doses | 25 |
targeted therapy | 25 |
therapeutic agent | 25 |
cells via | 25 |
hospital stay | 25 |
clinical findings | 25 |
plga nanoparticles | 25 |
less common | 25 |
patient compliance | 25 |
illicit drug | 25 |
receptor antagonists | 25 |
clinical response | 25 |
free fraction | 25 |
information regarding | 25 |
reactive protein | 25 |
promising results | 25 |
drug information | 25 |
different drugs | 25 |
graph neural | 25 |
health authorities | 25 |
cytotoxic effects | 25 |
new uses | 25 |
cell signaling | 25 |
one week | 25 |
proton channel | 25 |
among pwid | 25 |
cells using | 25 |
analysis showed | 25 |
positively charged | 25 |
clostridium difficile | 25 |
image gently | 25 |
another example | 25 |
ic values | 25 |
clinical manifestations | 25 |
drug molecule | 25 |
clinical implications | 25 |
therapeutic strategy | 25 |
coronavirus pneumonia | 25 |
ml kg | 25 |
drugs like | 25 |
early detection | 25 |
use authorization | 25 |
leading cause | 25 |
treatment period | 25 |
base balance | 25 |
feature set | 25 |
chitosan nanoparticles | 25 |
protective effect | 25 |
target sites | 25 |
lung cells | 25 |
literature search | 25 |
chest ct | 25 |
residence time | 25 |
drug usage | 25 |
antiretroviral drug | 25 |
available data | 25 |
standard deviation | 25 |
atypical pneumonia | 25 |
children aged | 25 |
fischer rats | 25 |
case series | 25 |
improve drug | 25 |
different cell | 25 |
dynamics simulations | 25 |
time points | 25 |
cervical cancer | 25 |
responsive drug | 25 |
us food | 25 |
viral drugs | 25 |
influenza viruses | 25 |
repurposing approach | 25 |
muscle cells | 25 |
response rate | 25 |
acute renal | 25 |
japanese respiratory | 24 |
acute generalized | 24 |
poorly understood | 24 |
repurposing drugs | 24 |
based methods | 24 |
age group | 24 |
based nanoparticles | 24 |
much higher | 24 |
prescribed drugs | 24 |
novel antiviral | 24 |
oral dose | 24 |
african trypanosomiasis | 24 |
side chain | 24 |
erythema multiforme | 24 |
community health | 24 |
novel therapeutic | 24 |
significant decrease | 24 |
fungal infections | 24 |
significant association | 24 |
squamous metaplasia | 24 |
hydrogen peroxide | 24 |
escape mutants | 24 |
health problem | 24 |
broad range | 24 |
provide information | 24 |
case study | 24 |
daily dose | 24 |
squamous epithelium | 24 |
recovery time | 24 |
control study | 24 |
web server | 24 |
systemic involvement | 24 |
executive summary | 24 |
therapeutic option | 24 |
fever virus | 24 |
vitro evaluation | 24 |
ii trial | 24 |
venom peptides | 24 |
pictorial review | 24 |
plasmid dna | 24 |
supplementary table | 24 |
old drugs | 24 |
liver cancer | 24 |
stimulus responsive | 24 |
may affect | 24 |
available drugs | 24 |
normal tissues | 24 |
building blocks | 24 |
ace receptor | 24 |
diseases like | 24 |
functional genomics | 24 |
older adults | 24 |
based design | 24 |
respiratory society | 24 |
signal intensity | 24 |
one year | 24 |
adaptive immune | 24 |
pharmacophore models | 24 |
social services | 24 |
study using | 24 |
care services | 24 |
molecule drugs | 24 |
hospital pharmacists | 24 |
hydroxychloroquine sulfate | 24 |
infections caused | 24 |
mechanically ventilated | 24 |
marketing authorization | 24 |
parietal cells | 24 |
docking scores | 24 |
gold standard | 24 |
channel blockers | 24 |
clinical experience | 24 |
structural biology | 24 |
version posted | 24 |
bioactive delivery | 24 |
bioactive compounds | 24 |
inhalation therapy | 24 |
generalized exanthematous | 24 |
resistant strains | 24 |
included patients | 24 |
manual cleaning | 24 |
extracellular matrix | 24 |
secondary metabolites | 24 |
using high | 24 |
therapeutic use | 24 |
novel approach | 24 |
various diseases | 24 |
subcellular localization | 24 |
new chemical | 24 |
se bond | 24 |
two cases | 24 |
resistant mutants | 24 |
healthy individuals | 24 |
renal disease | 24 |
imaging techniques | 24 |
overdose deaths | 24 |
vaccine development | 24 |
drosophila melanogaster | 24 |
low cost | 24 |
antiviral properties | 23 |
use disorders | 23 |
potential target | 23 |
cell count | 23 |
confirmed cases | 23 |
burst release | 23 |
myeloid leukemia | 23 |
docking score | 23 |
also demonstrated | 23 |
serious adverse | 23 |
positive bacteria | 23 |
will allow | 23 |
preliminary results | 23 |
vivo evaluation | 23 |
long half | 23 |
liquid chromatography | 23 |
clinical evidence | 23 |
novo drug | 23 |
disease severity | 23 |
spike glycoprotein | 23 |
analysed using | 23 |
steady state | 23 |
infected pneumonia | 23 |
past decade | 23 |
deficient mice | 23 |
precision medicine | 23 |
drug sensor | 23 |
people living | 23 |
enzymatic activity | 23 |
proton transport | 23 |
adverse reaction | 23 |
mitotic activity | 23 |
ct scans | 23 |
dry cough | 23 |
human liver | 23 |
renal insufficiency | 23 |
conducted using | 23 |
targeting ligands | 23 |
i clinical | 23 |
health outcomes | 23 |
success rate | 23 |
inflammatory drug | 23 |
proteins involved | 23 |
cutaneous adrs | 23 |
predicting drug | 23 |
learning methods | 23 |
may include | 23 |
bowel obstruction | 23 |
north america | 23 |
within days | 23 |
cell carcinoma | 23 |
bronchiolitis obliterans | 23 |
following administration | 23 |
pulmonary edema | 23 |
laboratory tests | 23 |
molecular biology | 23 |
secondary structure | 23 |
activated protein | 23 |
inhaled protein | 23 |
connectivity map | 23 |
new indication | 23 |
sore throat | 23 |
drug levels | 23 |
social justice | 23 |
graph completion | 23 |
nanostructured lipid | 23 |
intervention group | 23 |
antiviral compounds | 23 |
different mechanisms | 23 |
cell division | 23 |
tumor tissues | 23 |
ligand interactions | 23 |
induced liver | 23 |
analysis using | 23 |
tertiary care | 23 |
clinical improvement | 23 |
based approaches | 23 |
poisoned patients | 23 |
lymphatic vessels | 23 |
sensing ion | 23 |
excess charge | 23 |
health needs | 23 |
orphan drug | 23 |
drug policy | 23 |
comprehensive review | 23 |
ph values | 23 |
mediated endocytosis | 23 |
membrane fusion | 23 |
inhibit sars | 23 |
unique properties | 23 |
subcellular location | 22 |
large amounts | 22 |
three drugs | 22 |
tissue distribution | 22 |
wistar rats | 22 |
endoscope reprocessing | 22 |
assessed using | 22 |
big data | 22 |
hcv treatment | 22 |
colonic mucosa | 22 |
transcriptomic data | 22 |
first choices | 22 |
social distancing | 22 |
cells treated | 22 |
first choice | 22 |
bile acid | 22 |
mri findings | 22 |
injecting drug | 22 |
bronchoalveolar lavage | 22 |
disease states | 22 |
molecular descriptors | 22 |
genome sequence | 22 |
drug transporters | 22 |
medical applications | 22 |
based discovery | 22 |
metered dose | 22 |
virus association | 22 |
pump inhibitors | 22 |
acting antiviral | 22 |
animal testing | 22 |
hospital treatment | 22 |
aged years | 22 |
binding ligands | 22 |
induced hepatotoxicity | 22 |
lymphatic targeting | 22 |
drug research | 22 |
chikungunya virus | 22 |
air pollution | 22 |
rapid addition | 22 |
tyrosine kinases | 22 |
highly conserved | 22 |
also called | 22 |
drugs will | 22 |
focus group | 22 |
resistant tuberculosis | 22 |
butylated hydroxyanisole | 22 |
take advantage | 22 |
murine model | 22 |
genetic engineering | 22 |
international license | 22 |
asbestos fibres | 22 |
hek cells | 22 |
france please | 22 |
prescription drugs | 22 |
cardiac arrest | 22 |
inhibiting viral | 22 |
vitro activity | 22 |
great potential | 22 |
within min | 22 |
united kingdom | 22 |
second choices | 22 |
conformational changes | 22 |
medication use | 22 |
bowel irrigation | 22 |
will continue | 22 |
associated lymphoid | 22 |
molecular imaging | 22 |
loaded plga | 22 |
iii clinical | 22 |
treatment response | 22 |
service providers | 22 |
patients suffering | 22 |
social support | 22 |
much lower | 22 |
social capital | 22 |
patients showed | 22 |
gla loaded | 22 |
host interactome | 22 |
energy calculations | 22 |
related mortality | 22 |
carbonic anhydrase | 22 |
photothermal therapy | 22 |
lipid bilayer | 22 |
carcinoma cells | 22 |
veterinary medicine | 22 |
one hand | 22 |
chronic inflammation | 22 |
drug toxicity | 22 |
study will | 22 |
developing world | 21 |
basic research | 21 |
may show | 21 |
based materials | 21 |
mg every | 21 |
may vary | 21 |
see chapter | 21 |
binding mode | 21 |
tumor volume | 21 |
body surface | 21 |
cutaneous drug | 21 |
lead compounds | 21 |
polymer hybrid | 21 |
medicinal products | 21 |
asbestos bodies | 21 |
cell imaging | 21 |
release rate | 21 |
low toxicity | 21 |
nmr experiments | 21 |
six months | 21 |
chest wall | 21 |
protein nanoparticles | 21 |
syndromic surveillance | 21 |
general practitioners | 21 |
studies indicate | 21 |
genetic factors | 21 |
protein interactome | 21 |
enteric bacteria | 21 |
medical care | 21 |
human african | 21 |
experimental studies | 21 |
paediatric patients | 21 |
guar gum | 21 |
useful tool | 21 |
medicines agency | 21 |
support vector | 21 |
descriptive study | 21 |
quasispecies dynamics | 21 |
water solubility | 21 |
controlled delivery | 21 |
differentially expressed | 21 |
determine whether | 21 |
surface charge | 21 |
vitro model | 21 |
single drug | 21 |
new antibiotics | 21 |
drug eruption | 21 |
ventilated patients | 21 |
delivery vehicles | 21 |
vitro study | 21 |
blood circulation | 21 |
free radicals | 21 |
vitro assays | 21 |
liver transplantation | 21 |
results demonstrate | 21 |
quantitative structure | 21 |
cancer treatments | 21 |
brain injury | 21 |
interaction network | 21 |
one example | 21 |
therapeutic approaches | 21 |
cholinesterase inhibitors | 21 |
ct imaging | 21 |
class i | 21 |
new antiviral | 21 |
adsorption properties | 21 |
readily available | 21 |
already known | 21 |
often associated | 21 |
cardiac output | 21 |
may develop | 21 |
liver toxicity | 21 |
based pharmacophore | 21 |
potential candidates | 21 |
known drug | 21 |
mucous membranes | 21 |
give rise | 21 |
patients included | 21 |
cardiac hypertrophy | 21 |
basis set | 21 |
species differences | 21 |
cell activation | 21 |
using dft | 21 |
polymeric micelles | 21 |
highly expressed | 21 |
tumor vasculature | 21 |
qsar models | 21 |
compounding errors | 21 |
infection control | 21 |
gene silencing | 21 |
tissue damage | 21 |
maximum adsorption | 21 |
oral doses | 21 |
least two | 21 |
four patients | 21 |
including sars | 21 |
acute bronchitis | 21 |
coronavirus sars | 21 |
signifi cantly | 21 |
paneth cells | 21 |
environmental factors | 21 |
chemical compounds | 21 |
electronic properties | 21 |
antiviral treatment | 20 |
empiric therapy | 20 |
causative agent | 20 |
health emergency | 20 |
also seen | 20 |
treatment duration | 20 |
sectional study | 20 |
st century | 20 |
low doses | 20 |
drug selection | 20 |
cutaneous leishmaniasis | 20 |
viral hepatitis | 20 |
potential role | 20 |
competing interests | 20 |
neuraminidase inhibitors | 20 |
mucociliary clearance | 20 |
french addictovigilance | 20 |
safety profiles | 20 |
guinea pigs | 20 |
cmax ec | 20 |
developed countries | 20 |
new treatments | 20 |
two years | 20 |
kg per | 20 |
narrow therapeutic | 20 |
therapeutic approach | 20 |
cell lymphoma | 20 |
autodock vina | 20 |
old drug | 20 |
photodynamic therapy | 20 |
induced apoptosis | 20 |
gastrointestinal endoscopes | 20 |
pharmacokinetic data | 20 |
mental status | 20 |
cancer therapies | 20 |
homology model | 20 |
drug compounds | 20 |
medication reviews | 20 |
genetic testing | 20 |
classification system | 20 |
glandular mucosa | 20 |
dosage adjustment | 20 |
creatinine clearance | 20 |
gene set | 20 |
highly specific | 20 |
acid sequence | 20 |
educational exhibit | 20 |
silk fibroin | 20 |
cardiac function | 20 |
anticholinergic drugs | 20 |
urban poor | 20 |
recent progress | 20 |
set enrichment | 20 |
specific protein | 20 |
carbon atoms | 20 |
pharmaceutical services | 20 |
side chains | 20 |
strand breaks | 20 |
glomerular filtration | 20 |
systemic toxicity | 20 |
cardiac glycosides | 20 |
small size | 20 |
safety concerns | 20 |
fi eld | 20 |
solvation energy | 20 |
first case | 20 |
without affecting | 20 |
cell wall | 20 |
acid load | 20 |
elimination half | 20 |
development process | 20 |
influenza infections | 20 |
allergic reactions | 20 |
also important | 20 |
global pandemic | 20 |
adipose tissue | 20 |
least three | 20 |
studied using | 20 |
flow rate | 20 |
taz pipc | 20 |
repurposed drug | 20 |
metabolic pathways | 20 |
resistance mechanisms | 20 |
new generation | 20 |
various forms | 20 |
descriptor set | 20 |
future drug | 20 |
nuclear receptor | 20 |
hospital admission | 20 |
dose inhalers | 20 |
reference drugs | 20 |
stranded rna | 20 |
preliminary report | 20 |
antineoplastic agents | 20 |
effects like | 20 |
like peptide | 20 |
sensitive systems | 20 |
study demonstrates | 20 |
mental illness | 20 |
potential benefits | 20 |
pharmacological treatment | 20 |
hemolytic anemia | 20 |
silico methods | 20 |
identified using | 20 |
otitis media | 20 |
compounding pharmacies | 20 |
lessons learned | 20 |
powder inhalers | 20 |
psychotropic drugs | 20 |
target genes | 20 |
treatment option | 20 |
immunosuppressive drugs | 20 |
calculated using | 20 |
protein complex | 20 |
density functional | 20 |
european medicines | 20 |
hypersensitivity syndrome | 20 |
site residues | 20 |
model drug | 20 |
parenteral nutrition | 20 |
working group | 20 |
carrier systems | 20 |
fight covid | 20 |
mechanisms underlying | 20 |
ulcerative colitis | 20 |
protein drug | 20 |
free binding | 20 |
controlled clinical | 20 |
mean square | 20 |
us fda | 20 |
sars infection | 20 |
potential application | 20 |
approach using | 20 |
every hours | 20 |
silico studies | 20 |
toxicity profile | 19 |
sars cov | 19 |
chemical stability | 19 |
hiv treatment | 19 |
predicting protein | 19 |
combination therapies | 19 |
although many | 19 |
offending drug | 19 |
stratum corneum | 19 |
nucleocapsid protein | 19 |
activity relationships | 19 |
cardiac remodeling | 19 |
renal tubular | 19 |
presenting cells | 19 |
treatment guidelines | 19 |
data available | 19 |
cancer risk | 19 |
promising candidate | 19 |
pass metabolism | 19 |
high drug | 19 |
compounding pharmacy | 19 |
natural killer | 19 |
serum concentration | 19 |
lung function | 19 |
must also | 19 |
several days | 19 |
oral activated | 19 |
medical treatment | 19 |
large intestine | 19 |
develop new | 19 |
bacterial resistance | 19 |
potentially inappropriate | 19 |
severe adverse | 19 |
plga nps | 19 |
regression analysis | 19 |
medication discrepancies | 19 |
associated protein | 19 |
one case | 19 |
past two | 19 |
cardiac fibroblasts | 19 |
chronic pain | 19 |
kidney injury | 19 |
treatment failure | 19 |
within hours | 19 |
clinical signs | 19 |
specific targeting | 19 |
treated group | 19 |
phase clinical | 19 |
renal excretion | 19 |
less frequently | 19 |
protein bound | 19 |
mycoplasma pneumoniae | 19 |
th century | 19 |
agonist therapy | 19 |
sleeping sickness | 19 |
may serve | 19 |
metabolic activity | 19 |
disease management | 19 |
vitro data | 19 |
well established | 19 |
gastrointestinal endoscopy | 19 |
mass index | 19 |
tissue sections | 19 |
patients affected | 19 |
chronic disease | 19 |
maintenance treatment | 19 |
lung damage | 19 |
lung parenchyma | 19 |
may involve | 19 |
based systems | 19 |
glycogen synthase | 19 |
protein targets | 19 |
docking studies | 19 |
antibody fragments | 19 |
pulmonary arteries | 19 |
showed significant | 19 |
also performed | 19 |
analysis revealed | 19 |
urine samples | 19 |
takes place | 19 |
diagnostic imaging | 19 |
pivotal role | 19 |
take place | 19 |
release kinetics | 19 |
novel drugs | 19 |
pediatric patient | 19 |
principal component | 19 |
covalent inhibitors | 19 |
rhesus monkeys | 19 |
nasogastric tube | 19 |
test results | 19 |
histological features | 19 |
new class | 19 |
delivery devices | 19 |
drug therapies | 19 |
intellectual property | 19 |
kg twice | 19 |
ii study | 19 |
rational drug | 19 |
patient population | 19 |
therapeutic proteins | 19 |
histological examination | 19 |
biofilm formation | 19 |
investigate whether | 19 |
studies revealed | 19 |
depressive symptoms | 19 |
clinical significance | 19 |
systemic exposure | 19 |
physical activity | 19 |
following oral | 19 |
potential candidate | 19 |
active ingredient | 19 |
cell population | 19 |
practice guidelines | 19 |
known drugs | 19 |
patients presented | 19 |
histone deacetylase | 19 |
acid sequences | 19 |
iontophoretic drug | 19 |
protein therapeutics | 19 |
qualitative study | 19 |
randomized trial | 19 |
protective effects | 19 |
interaction networks | 19 |
therapeutic applications | 19 |
arachidonic acid | 19 |
gastric emptying | 19 |
potent inhibitors | 19 |
subcutaneous injection | 19 |
month period | 19 |
pharmacy practice | 19 |
will review | 19 |
day second | 19 |
drugbank database | 19 |
theragnostic tests | 19 |
five patients | 18 |
snake venom | 18 |
healthy adults | 18 |
mitochondrial dysfunction | 18 |
aided drug | 18 |
retrospective analysis | 18 |
transgenic mouse | 18 |
calcium phosphate | 18 |
inflammatory disease | 18 |
release syndrome | 18 |
nitride nanotubes | 18 |
concomitant use | 18 |
physiological conditions | 18 |
proinflammatory cytokines | 18 |
psychiatric disorders | 18 |
cyp enzymes | 18 |
body mass | 18 |
tuberculosis treatment | 18 |
gastric glands | 18 |
kinase activity | 18 |
statistical significance | 18 |
enzymes involved | 18 |
ribose methyltransferase | 18 |
protein structural | 18 |
high sensitivity | 18 |
initial phase | 18 |
inhibitory concentration | 18 |
deep matrix | 18 |
dna viruses | 18 |
powder inhaler | 18 |
previous work | 18 |
data obtained | 18 |
quercetin slms | 18 |
alveolar epithelium | 18 |
clinical setting | 18 |
inflammatory mediators | 18 |
safety issues | 18 |
mg per | 18 |
liver dysfunction | 18 |
antiviral efficacy | 18 |
mucous cells | 18 |
nasal mucosa | 18 |
goblet cell | 18 |
term treatment | 18 |
human breast | 18 |
high molecular | 18 |
covalent bond | 18 |
coronavirus spike | 18 |
circulation time | 18 |
age years | 18 |
pharmacological properties | 18 |
morphological changes | 18 |
associated proteins | 18 |
therapeutic doses | 18 |
serum concentrations | 18 |
exhibit will | 18 |
absorptive cells | 18 |
drugs approved | 18 |
dendritic cell | 18 |
dawley rats | 18 |
pulmonary function | 18 |
drug dosage | 18 |
higher sensitivity | 18 |
cell nmr | 18 |
hepatic metabolism | 18 |
whole blood | 18 |
eye drops | 18 |
beneficial effects | 18 |
liver enzymes | 18 |
transcriptase inhibitors | 18 |
ionizing radiation | 18 |
hepatic failure | 18 |
specific drugs | 18 |
may reduce | 18 |
viral disease | 18 |
hela cells | 18 |
several factors | 18 |
highly effective | 18 |
used drugs | 18 |
apparent efficacy | 18 |
also evaluated | 18 |
plasma half | 18 |
significant effect | 18 |
bioactive molecules | 18 |
culture medium | 18 |
lipid carriers | 18 |
genetically engineered | 18 |
many studies | 18 |
imaging modality | 18 |
local drug | 18 |
acetic acid | 18 |
recombinant human | 18 |
among different | 18 |
mean number | 18 |
binding energies | 18 |
starting point | 18 |
thermal stability | 18 |
chemical modifications | 18 |
clinically proven | 18 |
mg daily | 18 |
generated using | 18 |
sexually transmitted | 18 |
small amounts | 18 |
induced hypersensitivity | 18 |
one month | 18 |
related deaths | 18 |
continuous infusion | 18 |
nuclear factor | 18 |
mice treated | 18 |
small number | 18 |
fold greater | 18 |
pain management | 18 |
may offer | 18 |
abdominal pain | 18 |
drug solution | 18 |
evidence suggests | 18 |
diabetic rats | 18 |
human studies | 18 |
varying degrees | 18 |
low income | 18 |
visceral leishmaniasis | 18 |
label non | 18 |
may explain | 18 |
acute myeloid | 18 |
transdermal drug | 18 |
total cholesterol | 18 |
first reported | 18 |
three patients | 18 |
outpatient treatment | 18 |
significant impact | 18 |
molecular level | 18 |
drug sensitivity | 18 |
intravenous immunoglobulin | 18 |
filtration rate | 18 |
west nile | 18 |
expression data | 18 |
zeta potential | 18 |
measured using | 18 |
molecular modelling | 18 |
bipolar disorder | 18 |
using nmr | 18 |
binding proteins | 18 |
medical record | 18 |
diagnostic tests | 18 |
specific disease | 18 |
study demonstrated | 18 |
inflammatory process | 18 |
focus groups | 18 |
one third | 18 |
membrane transporters | 18 |
cell survival | 18 |
protein folding | 18 |
polymers based | 18 |
may need | 18 |
healthcare system | 18 |
potential anti | 18 |
covalent bonds | 18 |
dietary phytochemicals | 18 |
viral particles | 18 |
also reduced | 18 |
certain drugs | 18 |
massive fibrosis | 18 |
clinical pharmacokinetics | 17 |
identifi cation | 17 |
mol respectively | 17 |
treatment regimen | 17 |
rats fed | 17 |
pulmonary artery | 17 |
similar changes | 17 |
proposed method | 17 |
stimulating factor | 17 |
cells showed | 17 |
effl ux | 17 |
patient education | 17 |
vascular anomalies | 17 |
antimicrobial peptide | 17 |
pharmaceutical analysis | 17 |
confidence interval | 17 |
study design | 17 |
acute inflammatory | 17 |
first two | 17 |
degradation rate | 17 |
highly active | 17 |
galactosidase enzyme | 17 |
aerosolized drug | 17 |
antiviral action | 17 |
positive results | 17 |
identify drug | 17 |
pharmacy students | 17 |
particular drug | 17 |
shown apparent | 17 |
lipid metabolism | 17 |
regulatory agencies | 17 |
bond energy | 17 |
emerging viral | 17 |
studies performed | 17 |
authors also | 17 |
potential clinical | 17 |
european union | 17 |
interfering rna | 17 |
liver damage | 17 |
treatment outcomes | 17 |
total amount | 17 |
nucleotide sequence | 17 |
extensively studied | 17 |
protein complexes | 17 |
global hardness | 17 |
acinar cells | 17 |
another type | 17 |
liver cirrhosis | 17 |
ii clinical | 17 |
positive control | 17 |
risk management | 17 |
ct findings | 17 |
rat lung | 17 |
ten years | 17 |
residence times | 17 |
nitrobenzyl group | 17 |
common cause | 17 |
clinical application | 17 |
day course | 17 |
animal species | 17 |
endoscope channels | 17 |
urban settings | 17 |
also show | 17 |
drug deposition | 17 |
retrospective observational | 17 |
different levels | 17 |
old male | 17 |
glycyrrhizic acid | 17 |
receptor mediated | 17 |
pulmonary arterial | 17 |
alcian blue | 17 |
tissue culture | 17 |
differ significantly | 17 |
neutralizing antibodies | 17 |
immunodeficiency syndrome | 17 |
pulse sequence | 17 |
compounds may | 17 |
study aimed | 17 |
coated tablets | 17 |
odds ratio | 17 |
another drug | 17 |
previous study | 17 |
linear regression | 17 |
acquired immunodeficiency | 17 |
akt mtor | 17 |
herpes virus | 17 |
receptor agonist | 17 |
identifi ed | 17 |
progressive massive | 17 |
another important | 17 |
human blood | 17 |
become available | 17 |
heat shock | 17 |
acid substitutions | 17 |
identify new | 17 |
chemical properties | 17 |
might also | 17 |
outpatient clinic | 17 |
also shows | 17 |
tricyclic antidepressant | 17 |
collected data | 17 |
high prevalence | 17 |
improved drug | 17 |
high mortality | 17 |
population size | 17 |
outbreak associated | 17 |
class ii | 17 |
cell transformation | 17 |
ii receptor | 17 |
drug leads | 17 |
new therapies | 17 |
pol ii | 17 |
patients diagnosed | 17 |
fitness cost | 17 |
kidney function | 17 |
model using | 17 |
pharmacophore modeling | 17 |
cardiovascular system | 17 |
control drugs | 17 |
release profile | 17 |
transmission electron | 17 |
herbal products | 17 |
informed consent | 17 |
general practitioner | 17 |
promising drug | 17 |
clara cells | 17 |
blood cell | 17 |
renal dysfunction | 17 |
schematic representation | 17 |
vitro methods | 17 |
first day | 17 |
also associated | 17 |
taking advantage | 17 |
kg body | 17 |
randomly selected | 17 |
human respiratory | 17 |
predicted drugs | 17 |
studies will | 17 |
service delivery | 17 |
evaluated using | 17 |
high binding | 17 |
computational studies | 17 |
care facilities | 17 |
data sources | 17 |
cationic liposomes | 17 |
particularly important | 17 |
nude mice | 17 |
sensory neurons | 17 |
respiratory depression | 17 |
five years | 17 |
reduced toxicity | 17 |
finding new | 17 |
cleavage site | 17 |
potential risk | 17 |
virus rna | 17 |
mental disorders | 17 |
results indicated | 17 |
pediatric radiologist | 17 |
direct effect | 17 |
mm gbsa | 17 |
advanced breast | 17 |
human ace | 17 |
line therapy | 17 |
positive impact | 17 |
dose group | 17 |
blood plasma | 17 |
severe disease | 17 |
specific antibody | 17 |
synergistic effects | 17 |
clin pharm | 17 |
polymeric nanocapsules | 17 |
animal experiments | 17 |
laboratory data | 17 |
different studies | 17 |
experimental drugs | 17 |
inflammatory activity | 17 |
nucleotide polymorphisms | 17 |
coumarin derivatives | 17 |
manuscript www | 17 |
future perspectives | 17 |
cancer types | 16 |
biological properties | 16 |
large amount | 16 |
time consuming | 16 |
thymidine kinase | 16 |
also play | 16 |
common adverse | 16 |
basic drugs | 16 |
triblock copolymers | 16 |
coronavirus replication | 16 |
cancer therapeutics | 16 |
binding modes | 16 |
skin lesions | 16 |
type drug | 16 |
grapefruit juice | 16 |
single nucleotide | 16 |
homeless people | 16 |
enterochromaffin cells | 16 |
resistance genes | 16 |
cancer agents | 16 |
hyaluronic acid | 16 |
acoh redox | 16 |
studies show | 16 |
particularly useful | 16 |
biological barriers | 16 |
also considered | 16 |
zn acoh | 16 |
sialic acid | 16 |
ductus arteriosus | 16 |
thoracic society | 16 |
poor prognosis | 16 |
nucleoside reverse | 16 |
adjacency matrix | 16 |
originally developed | 16 |
commonly found | 16 |
inflammatory conditions | 16 |
among plhcv | 16 |
inhaled drug | 16 |
similar results | 16 |
congestive heart | 16 |
best practices | 16 |
vibrating mesh | 16 |
arterial hypertension | 16 |
low level | 16 |
dithiothreitol redox | 16 |
cellular targets | 16 |
virtual hits | 16 |
viral spike | 16 |
list prices | 16 |
light nir | 16 |
serum sickness | 16 |
medical imaging | 16 |
pneumonia outbreak | 16 |
lead monitoring | 16 |
energy metabolism | 16 |
ph responsive | 16 |
portal vein | 16 |
capping group | 16 |
medicinal plant | 16 |
antiinflammatory drugs | 16 |
approved medicines | 16 |
systemic absorption | 16 |
mg bd | 16 |
transferrin receptor | 16 |
multicenter study | 16 |
interacting proteins | 16 |
gastric glandular | 16 |
retinoic acid | 16 |
graph convolutional | 16 |
safe use | 16 |
release drug | 16 |
catalytic site | 16 |
protease enzyme | 16 |
signifi cant | 16 |
knowledge base | 16 |
light microscopy | 16 |
air activity | 16 |
therapeutic protein | 16 |
structural changes | 16 |
image noise | 16 |
adults hospitalized | 16 |
beagle dogs | 16 |
envelope protein | 16 |
squamous cell | 16 |
hiv disease | 16 |
alzheimer disease | 16 |
cycle arrest | 16 |
short period | 16 |
thiols redox | 16 |
positive patients | 16 |
receptor tyrosine | 16 |
biological evaluation | 16 |
old man | 16 |
mg micromotors | 16 |
phosphatase enzyme | 16 |
new quinolones | 16 |
dust pneumoconiosis | 16 |
glucuronidase enzyme | 16 |
intestinal epithelial | 16 |
pegylated liposomal | 16 |
resistant staphylococcus | 16 |
diseases society | 16 |
cytokine production | 16 |
previously published | 16 |
cytotoxic drugs | 16 |
scoring functions | 16 |
preclinical models | 16 |
indirect sharing | 16 |
will include | 16 |
null mice | 16 |
ang ii | 16 |
diagnostic accuracy | 16 |
human papillomavirus | 16 |
electrostatic interaction | 16 |
klebsiella pneumoniae | 16 |
median time | 16 |
target effects | 16 |
determined using | 16 |
patients reported | 16 |
lung delivery | 16 |
dual stimuli | 16 |
life threatening | 16 |
single oral | 16 |
low micromolar | 16 |
related coronavirus | 16 |
ec value | 16 |
rapid drug | 16 |
new approaches | 16 |
adverse side | 16 |
poorly water | 16 |
adsorption process | 16 |
low concentrations | 16 |
marketed drugs | 16 |
alveolar walls | 16 |
drugs including | 16 |
age range | 16 |
common among | 16 |
fat diet | 16 |
novo design | 16 |
host response | 16 |
plasmin enzyme | 16 |
related diseases | 16 |
acute kidney | 16 |
digestive system | 16 |
studies demonstrated | 16 |
multiple drug | 16 |
ester carbamate | 16 |
severe symptoms | 16 |
like receptor | 16 |
serum creatinine | 16 |
tumor targeting | 16 |
drug pairs | 16 |
dna double | 16 |
different diseases | 16 |
agents may | 16 |
worth noting | 16 |
cl protease | 16 |
scale production | 16 |
three types | 16 |
care service | 16 |
root mean | 16 |
bsa enzyme | 16 |
coumaric acid | 16 |
silico analysis | 16 |
ejection fraction | 16 |
feature selection | 16 |
observation period | 16 |